These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 15142676

  • 1. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
    Zhang Q, Wei D, Liu J.
    Cancer Lett; 2004 May 28; 208(2):179-86. PubMed ID: 15142676
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
    Qian F, Wei D, Zhang Q, Yang S.
    Biomed Pharmacother; 2005 Apr 28; 59(3):64-9. PubMed ID: 15795098
    [Abstract] [Full Text] [Related]

  • 4. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
    Liang G, Tang A, Lin X, Li L, Zhang S, Huang Z, Tang H, Li QQ.
    Int J Oncol; 2010 Jul 28; 37(1):111-23. PubMed ID: 20514403
    [Abstract] [Full Text] [Related]

  • 5. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J, Wang FP, Wei H, Liu G.
    Cancer Chemother Pharmacol; 2005 Feb 28; 55(2):179-88. PubMed ID: 15378274
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
    Wen Y, Zhao RQ, Zhang YK, Gupta P, Fu LX, Tang AZ, Liu BM, Chen ZS, Yang DH, Liang G.
    Oncotarget; 2017 May 02; 8(18):29760-29770. PubMed ID: 28423656
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells.
    Zhang XY, Li WG, Wu YJ, Bai DC, Liu NF.
    Can J Physiol Pharmacol; 2005 Mar 02; 83(3):309-18. PubMed ID: 15870845
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES, Na K, Bae YH.
    J Control Release; 2005 Mar 21; 103(2):405-18. PubMed ID: 15763623
    [Abstract] [Full Text] [Related]

  • 11. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX, Yang XH.
    Yao Xue Xue Bao; 2008 May 21; 43(5):461-6. PubMed ID: 18717331
    [Abstract] [Full Text] [Related]

  • 12. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent.
    Landis-Piwowar KR, Huo C, Chen D, Milacic V, Shi G, Chan TH, Dou QP.
    Cancer Res; 2007 May 01; 67(9):4303-10. PubMed ID: 17483343
    [Abstract] [Full Text] [Related]

  • 13. [MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro].
    Liang G, Zhang S, Huang ZM, Tang AZ.
    Ai Zheng; 2004 Apr 01; 23(4):401-5. PubMed ID: 15087027
    [Abstract] [Full Text] [Related]

  • 14. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
    Ren Y, Zhan X, Wei D, Liu J.
    Biomed Pharmacother; 2004 Nov 01; 58(9):520-6. PubMed ID: 15511610
    [Abstract] [Full Text] [Related]

  • 15. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB, Shen ZL, Fu J, Xu LZ.
    Phytomedicine; 2014 Sep 25; 21(11):1221-9. PubMed ID: 25172783
    [Abstract] [Full Text] [Related]

  • 16. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 25; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 17. In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933.
    Alaoui-Jamali MA, Schecter RL, Rustum YM, Centurioni MG, Lehnert S, Batist G.
    J Pharmacol Exp Ther; 1993 Mar 25; 264(3):1299-304. PubMed ID: 8450465
    [Abstract] [Full Text] [Related]

  • 18. Advantage of in vivo chemosensitivity assay to detect vincristine-resistance in a human epidermoid carcinoma xenograft.
    Abe Y, Yamazaki H, Oshika Y, Suto R, Tsugu A, Ota E, Satoh H, Ohnishi Y, Yanagawa T, Ueyama Y, Tamaoki N, Nakamura M.
    Anticancer Res; 1996 Mar 25; 16(2):729-34. PubMed ID: 8687121
    [Abstract] [Full Text] [Related]

  • 19. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate.
    Ray L, Kumar P, Gupta KC.
    Biomaterials; 2013 Apr 25; 34(12):3064-76. PubMed ID: 23357370
    [Abstract] [Full Text] [Related]

  • 20. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K, Un K, Tanaka K, Higaki K, Kimura T.
    J Control Release; 2009 Jan 05; 133(1):4-10. PubMed ID: 18840484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.